Severe Acute Respiratory Syndrome (SARS) Treatment Market Analysis By Drug Type(Antiviral, Antibacterial, Immunomodulators Drugs), By Route Of Administration(Oral, Injectable) & Forecast 2024-2035

  • 02/03/2023
  • 267
  • Healthcare & Life Sciences
The global severe acute respiratory syndrome (SARS) treatment market size was valued at USD 25.7 billion in 2021 and is projected to reach around USD 8.2 billion in 2030 exhibiting a CAGR of 14.5% in the forecasted period.

The rising cases of COVID-19, increase in the number of numerous contagious diseases caused by coronavirus are some of the key factors anticipated to drive the market. Additionally, fast expansion of the elderly population together with favourable government policies and initiatives for confirming cautionary treatments is projected to drive expansion of the global severe acute respiratory syndrome treatment market in the upcoming years. On the other hand, unavailability of medications during the pandemic and higher prices than actual cost for the treatment are anticipated to hinder the growth of severe acute respiratory syndrome (SARS) treatment market growth.

Growing cases of COVID-19 across the world is anticipated to boost the growth of the severe acute respiratory syndrome (SARS) treatment market throughout the forecasted period. For example, as per the World Health Organization (WHO), worldwide, till 2 November 2021, there have been 246,951,274 definite cases of COVID-19, with 5,004,855 deaths.
Moreover, development of new drugs and vaccines and growing drug approvals for the treatment of both SARS and COVID-19 is projected to increase the growth of the severe acute respiratory syndrome (SARS) treatment market. For example, in October 2020, the U.S. Food and Drug Administration (FDA) permitted the antiviral drug Veklury (Remdesivir) for the use in adult and paediatric patients for the treatment of COVID-19. Veklury is the first treatment for COVID-19 to get FDA approval.

The eruption of COVID-19 was initially noticed in a seafood market in Wuhan, China in mid- December 2019, has now extended to 215 nations worldwide. Most people infected with COVID-19 experience mild to moderate respiratory illness and recover without management, whereas some become extremely ill and need medical care. The fast pace of the coronavirus disease produced many research efforts to be introduced rapidly. China has more than 80 consecutively or pending clinical trials on possible treatments for COVID-19. Furthermore, the governments about the world are aiming on vaccination to inhibit the spread of the virus. As per the WHO, as of 1 November 2021, a total of 6,893,866,617 vaccine doses have been managed globally. This is predicted to propel the market growth.

Drug Class Insights
Based on drug class, the market is bifurcated into antiviral, antibacterial, and immunomodulators drugs. The biggest market share was held by the antibacterial category throughout the forecasted period. The factors can be ascribed to the high use of the product. However, the demand for the antibacterial drugs reduced during COVID, as they are not much effective for the diseases. 
Antiviral drugs like remdesivir and favipiravir, are the initial treatments for the SARS-CoV-2. Although, antibacterial drugs were recommended in some COVID cases where a secondary bacterial infection occurs.

Distribution Channel Insights
Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment is projected to hold the most significant CAGR in the forecasted period owing to the increasing hospitalization of COVID patients that needed treatment with antiviral medicines.
Moreover, the hospital pharmacies play a crucial role in the patient insurance for proper medications, dosages, and administration methods. Thus, patients prefer getting medicines from hospital pharmacies and in addition to that hospital pharmacies offer deductions on several medications that boost the market growth.

Region Insights
North America is projected to appear as one of the important regions in the global severe acute respiratory syndrome treatment market during the period of forecast. Such rule of the region is due to the existence of the well-developed infrastructure in the healthcare segment. Moreover, higher government funding for the purpose of inhibition of infectious diseases is estimated to add to the growth of the market in North America.

Asia Pacific is likely to show lucrative growth during the forecasted period, due to higher production of drugs for COVID-19 treatment by market companies to fight the pandemic. In May 2020, nearly 70 metric tons of hydroxychloroquine was made in India by Zydus Cadila and Ipca laboratories, and shipped to neighbouring countries beside with the U.S. Zydus Cadila and Ipca Labs are global pharmaceutical corporations that manufacture generic drugs and active pharmaceutical ingredients, respectively.

Key Companies Insights
The market for Severe acute respiratory syndrome (SARS) treatment is moderately competitive. With the rising applications of Severe acute respiratory syndrome (SARS) treatment, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Severe acute respiratory syndrome (SARS) treatment market, ultimately boosting the market growth.

Some of the key companies working in the global Severe acute respiratory syndrome (SARS) treatment market include:
• AstraZeneca Plc.
• Eli Lily & Company
• Boehringer Ingelheim
• Johnson & Johnson
• Ipca laboratories
• Takeda Ltd.
• AbbVie
• Roche Holding AG
• Pfizer Inc.
• Novartis
• GlaxoSmithKline plc.
• Cadila healthcare Ltd.
• Cipla Ltd.
• Hetero labs Ltd.
• Gilead Sciences Inc.
• Other players

Some of the Recent Developments:
• In September 2021, Pfizer Inc. and Merck & Co Inc. declared new trials of their investigational oral antiviral drugs to treat COVID-19; as the race to improve an easy-to-administer treatment for the possibly fatal disorder heats up.

• In March 2020, WHO developed a multiarm, multi-country clinical trial for possible coronavirus treatments, part of an aggressive effort to start-up the global search for medications to treat COVID-19.

• In March 2020, CEL-SCI Corporation developed the immunotherapy for the treatment of Covid-19 coronavirus using its LEAPS peptide technology.

By Drug Type
• Antiviral
• Antibacterial
• Immunomodulators Drugs

By Route Of Administration
• Oral
• Injectable

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
• Latin America
o Brazil
o Argentina
o Colombia
o South Africa
o Saudi Arabia
o Egypt
Base Year: 2023
Historic Year: 2016-2022
Forecast: 2024-2035

Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process

We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).


The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.

Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.


Select a license type that suits your business needs

Single User Access

US $3950

Only Three Thousand Nine Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $4950

Only Four Thousand Nine Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $5950

Only Five Thousand Nine Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI